Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 19/20 | 1.00 |
| ▸ | FPR3 | P25089 | 10/20 | 0.73 |
| ▸ | FPR1 | P21462 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9986557 | 1.00 | FPR2 (1.00) | FPR2FPR3FPR1 | |
| SCHEMBL727486 | 0.87 | FPR2 (0.77) | FPR2FPR3FPR1 | |
| SCHEMBL9985565 | 0.86 | FPR2 (0.87) | FPR2FPR3FPR1 | |
| SCHEMBL728721 | 0.86 | FPR2 (0.87) | FPR2FPR3FPR1 | |
| SCHEMBL727243 | 0.86 | FPR2 (1.00) | FPR2FPR3FPR1 | |
| SCHEMBL724717 | 0.86 | FPR2 (1.00) | FPR2FPR3FPR1 | |
| SCHEMBL9985273 | 0.86 | FPR2 (1.00) | FPR2FPR3FPR1 | |
| SCHEMBL9986432 | 0.86 | FPR2 (1.00) | FPR2FPR3FPR1 | |
| SCHEMBL854989 | 0.84 | FPR2 (1.00) | FPR2FPR3FPR1 | |
| SCHEMBL728485 | 0.84 | FPR2 (1.00) | FPR2FPR3FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795148-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3795148-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | ALLERGAN, INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN INC (US) | 2021-01-07 | — | — | US | disclosed |
| EP-2964213-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-2964213-B1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN INC (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. | 2017-08-03 | — | — | US | disclosed |
| WO-2014138046-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014138037-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2011163502-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008085-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885FPR3 3/4885FPR1 2/4885 |
| US-20140256685-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885FPR3 3/4885FPR1 2/4885 |
| US-20170216326-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885FPR3 3/4885FPR1 2/4885 |
| US-20110319454-A1 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY | FPR1, FPR2, FPR3 | FPR2 2/4885FPR3 3/4885FPR1 1/4885 |
| US-20210000846-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING DERMATOLOGICAL DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885FPR3 3/4885FPR1 2/4885 |
| US-20140256684-A1 | USE OF AGONISTS OF FORMYL PEPTIDE RECEPTOR 2 FOR TREATING OCULAR INFLAMMATORY DISEASES | FPR2, FPR1, FPR3 | FPR2 1/4885FPR3 3/4885FPR1 2/4885 |
| US-10899780-B2 | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases | FPR2, FPR1, FPR3 | FPR2 1/4885FPR3 3/4885FPR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.